IkT-001Pro

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameIkT-001Pro
Drug Alias NameImatinib prodrugIkT-001ProIkI 001IkI-001ProIkT-001 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsPlatelet-derived growth factor receptor inhibitorsSignal transduction pathway inhibitors
TargetsBcr-Abl tyrosine kinasePlatelet-derived growth factor receptor
Therapy Area/IndicationsPulmonary Arterial HypertensionLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesInhibikase Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesInhibikase Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPulmonary Arterial HypertensionLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A